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OBJECTIVE — Individualswithtype1diabeteshavedecreasedbonemineraldensity(BMD),
yet the natural history and pathogenesis of osteopenia are unclear. We have previously shown
that women with type 1 diabetes (aged 13–35 years) have lower BMD than community age-
matched nondiabetic control subjects. We here report 2-year follow-up BMD data in this cohort
to determine the natural history of BMD in young women with and without diabetes.
RESEARCH DESIGN AND METHODS — BMD was measured by dual-energy X-ray
absorptiometry at baseline and 2 years later in 63 women with type 1 diabetes and in 85
age-matched community control subjects. A1C, IGF-1, IGF binding protein-3, serum osteocal-
cin, and urine N-teleopeptide were measured at follow-up.
RESULTS — Afteradjustingforage,BMI,andoralcontraceptiveuse,BMDatyear2continued
to be lower in women 20 years of age with type 1 diabetes compared with control subjects at
the total hip, femoral neck, and whole body. Lower BMD values were observed in cases 20
years of age compared with control subjects; however, the differences were not statistically
signiﬁcant. Lower BMD did not correlate with diabetes control, growth factors, or metabolic
bone markers.
CONCLUSIONS — This study conﬁrms our previous ﬁndings that young women with type
1 diabetes have lower BMD than control subjects and that these differences persist over time,
particularlyinwomen20yearsofage.PersistenceoflowBMDaswellasfailuretoaccruebone
densityafterage20yearsmaycontributetotheincreasedincidenceofosteoporotichipfractures
seen in postmenopausal women with type 1 diabetes.
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T
ype 1 diabetes is an autoimmune
disorder resulting in loss of pancre-
atic insulin-producing -cells that
presents in childhood or early adulthood.
Along with increased risk of complica-
tions including retinopathy, nephropa-
thy, neuropathy, and cardiovascular
events, adults with type 1 diabetes have
decreased bone mineral density (BMD)
compared with control subjects (1,2). In
fact, osteoporosis is the most signiﬁcant
metabolic bone disease in individuals
with diabetes (3). Patients with diabetes
areatriskforosteoporosisanditscompli-
cations, including hip fracture (4,5).
Recent studies demonstrate that dia-
betesisassociatedwithalterationsinbone
health in children and adolescents. Pre-
pubertalandpubertalpatientswithtype1
diabetes(aged15years)havedecreased
bonemassmeasuredbothbyduel-energy
X-ray absorptiometry (DEXA) scan and
quantitative ultrasound (6–8). These ob-
servations suggest that adverse effects on
bone health may occur early after the di-
abetes diagnosis. Understanding the nat-
ural history of BMD changes in young
adults with type 1 diabetes may elucidate
how the disease progresses and provide
opportunities for prevention of signiﬁ-
cant bone loss and, presumably, fracture.
We demonstrated previously that
premenopausal women (aged 20–35
years) with type 1 diabetes have lower
BMDatthefemoralneckandlateralspine
than nondiabetic control subjects (7).
This difference was not associated with
diabetes duration, metabolic control, or
biochemicalmarkersofboneformation,a
ﬁnding supported by previous work
(9,10). Few studies have followed young
women longitudinally to assess whether
bonemineralacquisitionorturnoverplay
aroleinthenaturalhistoryoflowBMDin
diabetes. The aim of this study was to ad-
dress the natural history of bone metabo-
lism in type 1 diabetes by performing a
follow-upDEXA2yearsafterbaselineen-
rollment to determine whether differ-
ences persist over time.
RESEARCH DESIGN AND
METHODS—Female study partici-
pants were recruited from participants in
a cross-sectional study assessing BMD in
young women with type 1 diabetes and
age-matched community control subjects
(7). Cases for the cross-sectional study
(baseline) were recruited from a regional
tertiary hospital pediatric diabetes center
and from endocrinology practices in
Western New York. At the time of the ini-
tial study, the diabetes center followed
over 600 patients aged 2–21 years with
type 1 diabetes. Female patients aged
13–21 years in that clinical center were
offered the opportunity to participate in
thebaselinestudy(n138).Recruitment
of older women involved contacting
former center patients (aged 21 years),
patients from regional endocrinology
practices, and affected relatives of sub-
jects screened by our diabetes center for
the Diabetes Prevention Trial. The com-
parisongroupincludedyoungwomenre-
cruited from the same region as the case
subjects; most were classmates or ac-
quaintances of the case subjects or were
volunteers who learned of the study
through ﬂyers posted at the university
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72 case subjects (diabetes duration 2
years)and91controlsubjectsaged13–37
years who were at least 2 years postmen-
archal (7).
All type 1 diabetic case subjects and
nondiabetic control subjects who partici-
patedinthebaselinestudywererecruited
2 years later to assess change in BMD
over time. Contact was maintained with
study participants between the baseline
and follow-up exam via phone and mail.
Inclusion criteria for the follow-up study
were participation in the baseline study,
current negative pregnancy test, and
signed informed consent. For individuals
younger than 18 years of age, a parent
cosignedtheinformedconsent.Exclusion
criteria for both the baseline and fol-
low-upstudyincludedsystemicillnessaf-
fecting BMD (other than diabetes), other
endocrine disorders (except autoimmune
thyroiditis), and diagnosis of juvenile os-
teoporosis or other bone disease. Individ-
uals with autoimmune thyroiditis on
levothyroxine therapy were biochemi-
cally euthyroid. The study was approved
by the institutional review boards of the
Women and Children’s Hospital of Buf-
faloandtheUniversityatBuffalo.Atbase-
line, study participants completed
questionnaires relating to personal and
family health, lifestyle habits, dietary in-
take (food frequency questionnaire), and
medication intake including use of cal-
cium supplements. Participants also re-
ported prior fracture history, menstrual
history, and demographic information.
For participants with type 1 diabetes, in-
formation on disease duration, insulin
dose schedule (injections versus continu-
ous subcutaneous insulin infusion), and
diabetes complications were reported.
Weight, height, and blood pressure were
measured using standard protocols. BMI
was calculated as weight in kilograms di-
vided by the square of height in meters.
DEXA (Hologic QDR-4500A; Ho-
logic,Waltham,MA)wasusedtomeasure
BMD in the anterior/posterior (L1–4)
spine, total hip, femoral neck, total fore-
arm, and whole body. All scans were per-
formed on the same device for both visits.
Asingletechnicianperformedallbaseline
scans and 65% of the follow-up scans;
two additional technicians performed the
remainder of the follow-up scans (27%
and 7%, respectively). Coefﬁcients of
variation(CVs)weredeterminedformea-
sures of all sites for all technicians
throughout the study and were all 1%
throughout the study. A daily manufac-
turer quality control phantom was done
toensurenodrift.Therewerenosoftware
upgrades during the follow-up interval.
The following biomarkers were
measured in nontimed blood samples:
serum osteocalcin, IGF-1, IGF binding
protein (IGFBP)-3 (by radioimmuno-
assay), and A1C (by high-performance
liquid chromatography with Bio-Rad
variant; Bio-Rad, Richmond, CA). Ran-
dom urinary N-teleopeptide levels were
measured by enzyme-linked immuno-
absorbent assay. Blood samples were
processed using standard protocols. Se-
rum for hormonal assays was frozen at
80°Candstoreduntilsentforanalysis
in batches to Esoterix Laboratory (Cala-
basas Hills, CA). A1C (fresh plasma)
was assayed in a sequential fashion at
the Women and Children’s Hospital of
Buffalo laboratory (Kaleida Health).
Urine samples were stored frozen at
80°C. For hormone measurements,
intra-assayCVwas3%forN-telopeptide,
6% for IGF-1 and osteocalcin, and 13% for
IGFBP-3. Interassay CV was 7% for N-
Telopeptide,9.7%forIGF-1,13%foros-
teocalcin,and17%forIGFBP-3(Esoterix
Laboratories).
Datafromstudyparticipantswerean-
alyzed in stratum based on age at initial
enrollment (7). Demographic, lifestyle,
metabolic characteristics, and BMD were
compared between diabetic case subjects
and nondiabetic control subjects, strati-
ﬁed by age. Comparisons were made for
baselinedifferences,differencesatfollow-
up, and percent change between the two
time points. Results were presented as
both unadjusted comparisons and com-
parisons of adjusted means (adjusted for
age, BMI, and oral contraceptive [OC]
use). Unadjusted differences for continu-
ous variables were examined using Stu-
dent’s t test and for categorical variables
using the 
2 test. ANOVA was used for
adjusted models. In case subjects only,
A1C levels were compared across
younger and older age-groups. Data anal-
yses were performed using SAS version 8
(SAS, Cary, NC). Post hoc power analysis
of follow-up total hip BMD (adjusted for
age, BMI, and OC use) indicated that our
dataset of 63 case subjects (n  37, 20
years of age) and 85 control subjects (n 
36,20yearsofage)gaveourstudy80%
power to detect a difference between case
andcontrolsubjectswithanof0.05and
a target effect size of 0.45 in women 20
years of age and 0.63 in those 20 years
of age.
RESULTS—Table 1 includes baseline
and follow-up characteristics of women
who participated in this follow-up study.
For comparative purposes, study subjects
were grouped by age at baseline (20
years/20 years). The follow-up group
included 63 women with type 1 diabetes
(58.7% 20 years of age) and 85 control
subjects without diabetes (42.4% 20
yearsofage)atages15–39yearsatenroll-
ment. The average follow-up time was
2.14years.Oftheparticipantsinthebase-
linestudywithdiabetes,87.5%(63of72)
participated in this follow-up study, and
93.4% (85 of 91) of control subjects par-
ticipatedinbothexaminations.Moresub-
jects from the baseline cohort 20 years
of age were lost to follow-up (13.8 vs.
3.94%,cohort20yearsofage),withthe
highest attrition being from individuals
with diabetes 20 years of age (21.2%).
The primary reason for loss to follow-up
wasgeographicrelocation.Participantsin
this follow-up study were predominantly
non-Hispanic Caucasian (95%) and were
similarinageatmenarcheandyearssince
menarche. Participants 20 years of age
with diabetes used OC therapy longer
than control subjects (P  0.05). Al-
though few participants were smokers,
more women with diabetes reported cur-
rent smoking; there were no smokers
among the control subjects 20 years of
age.
At follow-up, women with diabetes,
particularly the older women, continued
to have higher BMI than control subjects.
Weight change (in percent) was not sig-
niﬁcantly different over the follow-up pe-
riod. As reported previously, more
patients in the older cohort were using
continuous subcutaneous insulin infu-
sion (P  0.01, data not shown). While a
trend toward lower daily insulin require-
ment was present in the older cohort
(0.86 	 0.42 vs. 0.75 	 0.22 units   kg
1
  day
1), that difference was not statisti-
cally signiﬁcant. Subjects 20 years of
age were more likely to have diabetes-
related complications, although no statis-
tical differences were found. More
younger subjects were on levothyroxine
therapy.
Table 2 presents BMD values at base-
lineandfollow-upforeachbodysitemea-
sured. Unadjusted means and means
adjusted for age, BMI, and OC use are
shown stratiﬁed by age-group and diabe-
tes diagnosis. In those 20 years of age,
both case and control subjects had an in-
crease in BMD over the 2-year interval.
The percent increase in BMD from base-
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ferent between younger subjects and
control subjects. For all participants in
the population 20 years of age, the
BMD from baseline to follow-up re-
mained stable.
Signiﬁcant differences in BMD were
identiﬁed at the total hip, femoral neck,
and whole body in the case subjects 20
years of age compared with the control
subjects.Asinthepreviousreport,nodif-
ferences in BMD were seen between
groups in the younger cohort. In the ad-
justed model (for age, BMI, and OC use),
BMD values at the total hip (baseline, P 
0.003;follow-up,P0.007)andfemoral
neck (baseline and follow-up, P  0.001)
were signiﬁcantly lower in older women
withdiabetescomparedwithcontrolsub-
jects. After adjustment, the whole-body
BMD was no longer signiﬁcantly different
between case and control subjects; how-
ever, both age-groups showed a trend to-
ward lower whole-body BMD in the case
subjects. Further adjustment for dietary
intakeofcalciumandvitaminDaswellas
physical activity did not alter the BMD
results (data not shown). When the anal-
ysiswasrestrictedtononsmokers,thead-
justed means changed very little. For the
older cohort, however, the P values were
attenuated for the total hip (P  0.017)
and whole body (P  0.215). In non-
smokers 20 years of age, the percent
change difference at the total hip became
more pronounced between case and con-
trolsubjectsandreachedstatisticalsignif-
icance (P  0.008).
Overall, IGF-1 levels were lower for
all groups compared with baseline (Table
3). This is consistent with a physiologic
decrease in IGF-1 in postteenage years
(Esoterix normative data 11). At the
2-year follow-up, however, the IGF-1
level was signiﬁcantly lower in the
youngerdiabeticsubjectsthaninthecon-
trol subjects, although still within the
normal range. IGF-1 levels were not sta-
tistically different between diabetic par-
ticipants and control subjects in the older
cohort. Within the older age-group,
IGFBP-3 levels were lower in participants
with diabetes than in control subjects
(P  0.05). IGFBP-3 levels were compa-
rable for control and diabetic subjects in
the cohort 20 years of age.
Serum osteocalcin levels were lower
at follow-up for all groups, even with in-
creasedbonemineralaccrualinthegroup
20 years of age (Table 3). There was no
difference in osteocalcin or N-teleopep-
tide levels between case and control sub-
jects 20 years of age (Table 3). After
adjusting for age and BMI, case subjects
had signiﬁcantly lower osteocalcin levels
than control subjects in the population
20 years of age (P  0.04; Table 3). In
addition, the percent change in osteocal-
cin level from baseline to follow-up was
signiﬁcantly different in diabetic women
20 years of age compared with control
subjects after adjustment (P  0.03).
Markers of bone formation did not corre-
late with BMD in our subjects.
Metabolic control, as measured by
A1C, was poorer in the younger diabetic
cohort, as we reported previously (7).
Overall metabolic control was stable
within a given age stratum between the
baseline and follow-up studies. No corre-
lation was found between A1C and any of
the BMD measurements (data not pre-
sented). When evaluating for associations
between metabolic control and BMD
measurements that were statistically
lower in case than in control subjects at
follow-up (Table 2), the Pearson correla-
tion coefﬁcient (R value) for A1C and
BMD was between 0.121 (total hip) and
0.334(femoralneck)(P0.095,datanot
shown). As in our previous study, there
was no association found between BMD
and diabetes duration, baseline A1C, or
years since menarche.
CONCLUSIONS —While longitudi-
nal studies have examined the effect of
insulin therapy on BMD in patients with
long-standing type 1 diabetes (12), few
Table 1—Demographic and clinical characteristics of the study population
Age 20 years Age 20 years
Control
Type 1
diabetic P* Control
Type 1
diabetic P*
n 36 37 49 26
Baseline characteristics
Age (years) 15.9 	 1.5 16.2 	 1.8 0.478 25.7 	 4.4 27.3 	 4.1 0.124
Non-Hispanic white 32 (88.9) 37 (100) 47 (95.9) 25 (96.2)
Other race 4 (11.1) 0 (0) 0.037 2 (4.1) 1 (3.9) 0.961
Age at menarche (years) 12.4 	 1.03 12.3 	 1.40 0.653 12.9 	 1.17 13.2 	 1.40 0.220
Years from menarche 4.0 	 1.6 4.3 	 2.0 0.452 13.2 	 4.5 14.6 	 4.2 0.204
OC use 4 (11.1) 5 (13.5) 0.755 33 (67.4) 20 (76.9) 0.386
Years on OC 0.078 	 0.28 0.092 	 0.37 0.859 2.24 	 2.76 3.94 	 4.06 0.050
Smoking status 0 (0) 7 (18.9) 0.006 3 (6.1) 4 (16.0) 0.170
Follow-up
Follow-up years 2.10 	 0.27 2.19 	 0.30 0.226 2.16 	 0.27 2.12 	 0.19 0.546
Weight (kg)
Baseline 61.5 	 11.0 65.2 	 8.5 0.105 62.7 	 9.5 69.0 	 8.5 0.006
Follow-up 63.7 	 11.4 66.9 	 9.3 0.187 63.9 	 11.3 70.2 	 10.3 0.020
Change 2.21 	 4.52 1.69 	 4.41 0.616 1.21 	 4.96 1.21 	 5.0 0.998
BMI (kg/m
2)
Baseline 22.6 	 3.5 24.2 	 2.9 0.036 22.5 	 3.0 25.0 	 2.8 0.001
Follow-up 23.1 	 3.6 24.4 	 2.7 0.093 22.9 	 3.7 25.4 	 3.5 0.007
Change 0.53 	 1.7 0.19 	 1.6 0.374 0.38 	 1.9 0.42 	 1.8 0.927
Data are means 	 SD and n (%). *P values by Student’s t test for continuous and 
2 test for categorical variables.
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metabolic bone disease in younger
women. Here we present BMD data for a
well-characterized cohort of young
women with type 1 diabetes at baseline
and2yearslater.Thebaselinestudydem-
onstratedthattheoldercohorthadsignif-
icantly lower BMD at the femoral neck
and lateral spine than age-matched con-
trol subjects (7). The data presented here
demonstrate that case subjects in the
older cohort had persistently lower BMD
than age-matched healthy control sub-
jects. In this cohort, BMD at the total hip
and femoral neck remained lower than in
control subjects after adjusting for age,
BMI,andOCuse,evenwithnosigniﬁcant
decrease in BMD from baseline to fol-
low-up (Table 2). Similar to our initial
study,therewasnodifferenceinBMDbe-
tween women with diabetes aged 20
years and control subjects at any of the
sites measured. However, there was a
trend toward lower BMD at the total hip
and whole body in women with diabetes.
This difference occurred in the face of
BMD increases (percent change) at both
the total hip and whole body in this pop-
ulation, suggesting that bone mineral ac-
crual is altered in a subtle manner during
late adolescence in women with type 1
diabetes.
Individuals with type 2 diabetes have
Table 2—BMD measurements (g/cm
2) by age-group
Age 20 years Age 20 years
Control Type 1 diabetic P Control Type 1 diabetic P
n 36 37 49 26
Unadjusted data
Total hip*
Baseline 0.975 	 0.12 0.950 	 0.11 0.341 0.973 	 0.12 0.906 	 0.10 0.015
Follow-up 0.983 	 0.12 0.953 	 0.11 0.265 0.968 	 0.11 0.910 	 0.10 0.029
Percent change 0.87 	 3.67 0.32 	 3.02 0.486 0.55 	 2.58 0.50 	 2.51 0.092
Femoral neck*
Baseline 0.884 	 0.13 0.870 	 0.10 0.613 0.876 	 0.12 0.795 	 0.10 0.003
Follow-up 0.891 	 0.12 0.872 	 0.10 0.468 0.867 	 0.12 0.790 	 0.09 0.005
Percent change 1.02 	 3.71 0.31 	 3.54 0.407 0.68 	 3.56 0.49 	 3.31 0.823
Wrist*
Baseline 0.533 	 0.06 0.534 	 0.04 0.904 0.565 	 0.04 0.553 	 0.04 0.245
Follow-up 0.549 	 0.05 0.552 	 0.04 0.775 0.565 	 0.04 0.551 	 0.04 0.163
Percent change 3.19 	 2.85 3.42 	 2.46 0.716 0.041 	 1.46 0.41 	 1.31 0.190
A/P spine*
Baseline 0.991 	 0.11 0.978 	 0.09 0.594 1.055 	 0.11 1.029 	 0.11 0.335
Follow-up 1.010 	 0.11 1.00 	 0.10 0.747 1.059 	 0.11 1.032 	 0.12 0.329
Percent change 1.96 	 3.88 2.40 	 3.67 0.626 0.36 	 2.43 0.26 	 2.88 0.868
Whole body*
Baseline 1.090 	 0.08 1.069 	 0.08 0.274 1.142 	 0.08 1.097 	 0.09 0.031
Follow-up 1.106 	 0.08 1.084 	 0.08 0.251 1.138 	 0.08 1.096 	 0.09 0.041
Percent change 1.51 	 2.12 1.44 	 2.18 0.890 0.33 	 2.00 0.04 	 1.92 0.556
Adjusted data
Total hip†
Baseline 0.986 	 0.13 0.940 	 0.10 0.067 0.979 	 0.12 0.898 	 0.10 0.003
Follow-up 0.993 	 0.12 0.943 	 0.10 0.058 0.972 	 0.12 0.902 	 0.09 0.007
Percent change 0.80 	 3.67 0.39 	 3.02 0.598 0.55 	 2.58 0.50 	 2.51 0.124
Femoral neck†
Baseline 0.895 	 0.13 0.859 	 0.10 0.158 0.883 	 0.12 0.783 	 0.10 0.001
Follow-up 0.901 	 0.12 0.862 	 0.10 0.120 0.876 	 0.12 0.777 	 0.09 0.001
Percent change 0.89 	 3.71 0.44 	 3.54 0.610 0.57 	 3.42 0.69 	 3.31 0.887
Wrist†
Baseline 0.538 	 0.06 0.529 	 0.04 0.413 0.566 	 0.04 0.551 	 0.04 0.168
Follow-up 0.553 	 0.05 0.548 	 0.04 0.630 0.566 	 0.04 0.550 	 0.04 0.116
Percent change 2.99 	 2.85 3.62 	 2.46 0.257 0.002 	 1.38 0.34 	 1.31 0.353
A/P spine†
Baseline 1.002 	 0.11 0.968 	 0.09 0.117 1.060 	 0.11 1.020 	 0.11 0.169
Follow-up 1.020 	 0.11 0.992 	 0.10 0.243 1.062 	 0.11 1.026 	 0.12 0.215
Percent change 1.88 	 3.88 2.47 	 3.67 0.498 0.20 	 2.41 0.55 	 2.88 0.601
Whole body†
Baseline 1.097 	 0.08 1.063 	 0.08 0.055 1.142 	 0.08 1.097 	 0.09 0.043
Follow-up 1.113 	 0.08 1.078 	 0.08 0.061 1.138 	 0.08 1.097 	 0.09 0.065
Percent change 1.48 	 2.12 1.47 	 2.18 0.986 0.39 	 2.01 0.09 	 1.91 0.344
Data are means 	 SD. *P values by Student’s t test. †P values by ANCOVA, adjusted for age, BMI, and OC use. A/P, anterior/posterior.
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control subjects (13), in part due to the
mechanical load of obesity. In our study,
women with type 1 diabetes had higher
BMI than control subjects. However,
BMD continued to be lower in older
women with type 1 diabetes, even after
adjustingforBMI;thus,overweightstatus
does not confer protection against poor
bone mineralization in these young
women.
Although the younger cohort had
poorer diabetes control than the older co-
hort, we were again unable to demon-
strate an association between BMD
measures and metabolic control, as mea-
sured by A1C. Others have reported sim-
ilar ﬁndings with respect to BMD in
children and adolescents with diabetes
(14). A1C measures short-term diabetes
control; perhaps cumulative life-time gly-
cemic control is a better indicator of os-
teoporotic risk. This hypothesis is
supported by studies demonstrating that
decreased lumbar spine and femoral neck
BMD in adults with type 1 diabetes is as-
sociated with retinopathy, nephropathy,
and peripheral neuropathy, all of which
are long-term complications of poor met-
abolic control (15–17). In addition, our
data did not ﬁnd a correlation between
diabetes duration and BMD, further sup-
porting a possible relation to lifetime dia-
Table 3—Hormonal values and glycemic control by age-group in type 1 diabetic young women and nondiabetic control subjects
Age 20 years Age 20 years
Control Type 1 diabetic P Control Type 1 diabetic P
n 36 37 49 26
Unadjusted data
IGF-1 (ng/ml)*
Baseline 308 	 67.4 280 	 81.8 0.121 222 	 89.6 209 	 64.6 0.512
Follow-up 288 	 78.1 213 	 83.4 0.001 166 	 48.7 147 	 41.1 0.097
Percent change 3.5 	 30.2 20.9 	 27.2 0.013 20.4 	 21.2 25.7 	 25.7 0.345
IGFBP-3 (mg/ml)*
Baseline 3.2 	 0.51 3.0 	 0.60 0.234 2.9 	 0.78 2.8 	 0.72 0.527
Follow-up 3.3 	 0.91 3.1 	 0.73 0.232 2.9 	 0.75 2.6 	 0.65 0.043
Percent change 3.7 	 13.3 3.4 	 20.9 0.182 4.0 	 29.8 6.1 	 21.1 0.129
Osteocalcin (ng/ml)*
Baseline 18.9 	 8.3 19.3 	 8.8 0.829 10.4 	 5.8 9.7 	 5.2 0.615
Follow-up 12.6 	 6.7 10.3 	 4.6 0.097 7.7 	 2.9 6.7 	 3.3 0.155
Percent change 22.9 	 52.9 34.4 	 44.1 0.317 4.3 	 56.2 22.8 	 35.3 0.138
N-telopeptides/creatinine (nmol/l
BCE/mmol/l creatinine)*
Baseline 76.9 	 35.9 80.3 	 49.4 0.737 32.2 	 12.7 34.0 	 18.1 0.614
Follow-up 58.1 	 28.3 47.9 	 23.7 0.099 34.1 	 17.5 32.0 	 13.8 0.604
Percent change 20.7 	 28.9 26.3 	 40.3 0.503 24.0 	 91.3 7.0 	 47.1 0.378
Adjusted data
IGF-1 (ng/ml)†
Baseline 310 	 67.4 279 	 81.8 0.090 217 	 89.6 218 	 64.6 0.942
Follow-up 284 	 78.1 216 	 83.4 0.001 161 	 48.7 155 	 41.1 0.558
Percent change 5.1 	 30.2 19.3 	 27.2 0.043 20.2 	 21.2 26.0 	 25.7 0.347
IGFBP-3 (mg/ml)†
Baseline 3.2 	 0.51 3.0 	 0.60 0.258 2.8 	 0.78 3.0 	 0.72 0.525
Follow-up 3.3 	 0.91 3.1 	 0.73 0.434 2.9 	 0.75 2.6 	 0.65 0.127
Percent change 4.3 	 13.3 4.0 	 20.9 0.119 5.3 	 29.8 8.4 	 21.1 0.051
Osteocalcin (ng/ml)†
Baseline 18.0 	 8.3 20.3 	 8.8 0.187 10.1 	 5.8 10.2 	 5.2 0.952
Follow-up 12.2 	 6.7 10.6 	 4.6 0.221 8.0 	 2.9 6.3 	 3.3 0.038
Percent change 20.9 	 52.9 36.4 	 44.1 0.188 0.24 	 56.2 30.9 	 35.3 0.023
N-telopeptides/creatinine (nmol/l
BCE/mmol/l creatinine)†
Baseline 74.4 	 35.9 82.9 	 49.4 0.331 32.0 	 12.7 34.5 	 18.1 0.523
Follow-up 57.4 	 28.3 48.6 	 23.7 0.130 34.5 	 17.5 31.1 	 13.8 0.436
Percent change 18.4 	 28.9 28.7 	 40.3 0.214 26.8 	 91.3 1.7 	 47.1 0.238
A1C (%)‡
Baseline 8.2 	 1.2 7.4 	 0.9 0.008
Follow-up 8.5 	 1.5 7.6 	 0.9 0.007
Percent change 4.3 	 16.0 3.5 	 12.3 0.833
Dataaremeans	SD.Labvalueswerecalculatedinthecohortaged20yearsforIGF-1,telopeptides/creatinine,andA1C(casesubjects,n36);IGFBP-3(control
subjects, n  23; case subjects, n  22); and osteocalcin (case subjects, n  36); and in the cohort aged 20 years for osteocalcin (control subjects, n  46; case
subjects, n  25). *P values by Student’s t test. †P values by ANCOVA, adjusted for age and BMI. ‡P values by Student’s t test in case subjects between age-groups.
BCE, bone collagen equivalent.
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chronic hyperglycemia related to osteo-
blastfunction,osteoclastactivity,andfor-
mation of advanced glycosylated end
products that may impact bone quality as
well as bone quantity (18) are difﬁcult to
measure in a systematic fashion.
Theroleofinsulinasadirectanabolic
agent in bone metabolism is unclear (19).
Animal models of spontaneous and phar-
macologically induced diabetes demon-
strate that as insulinopenia develops,
there is a suppression of osteoblast mark-
ers (20). It has been postulated that in
addition to insulinopenia, relative IGF-1
deﬁciency, whether systemic or local,
contributes to low BMD in diabetes.
IGF-1 levels are lower in individuals with
type 1 diabetes, and poor glycemic con-
trol negatively impacts IGF-1 production
bytheliver.Inadultswithtype1diabetes,
IGF-1 levels were lower in individuals
with osteopenia at the femoral neck (1).
Additionally, in a study of 127 children
(aged 6–20 years) with diabetes, low
bone mineral content correlated with low
IGF-1 levels (9). In our study, IGF-1 lev-
els of case subjects were signiﬁcantly
lower than those of control subjects only
for the younger cohort. However, IGF-1
levelsofsubjectswithdiabeteswerelower
in the group 20 years of age compared
with the group 20 years of age, and
IGFBP-3 levels in the older cohort were
signiﬁcantlylowercomparedwithcontrol
subjects. Given that no biochemical
markers of bone metabolism correlated
with BMD at the hip or femoral neck in
our study, it could be hypothesized that a
cumulative history of insulinopenia and
low IGF-1 levels are better correlates for
low bone density. These proposed mech-
anisms require further exploration.
Our data demonstrate signiﬁcant dif-
ferences in BMD at the femoral neck and
total hip that are likely to be clinically sig-
niﬁcant and may explain why women
with type 1 diabetes have an increased
risk of hip fractures later in life (4,5). Our
data also indicate that alterations in bone
mineral accrual occur within years of
achievement of peak bone mass and that
there is not a later period of “catch-up”
bone mineralization. The most clinically
relevant factor is whether a decrease in
BMD correlates with fracture risk, which
cannot be determined in this study. Be-
sides BMD, multiple factors impact frac-
ture risk including, but not limited to,
age,nutritionstatus,smokinghistory,de-
gree of frailty, and fracture history (21).
The well-characterized population,
the large percentage of women who par-
ticipated in the follow-up study, and the
standard procedures used in this longitu-
dinal study all represent signiﬁcant
strengths. Yet, we acknowledge certain
limitations. The study population is
small,limitingitsabilitytodetecttruedif-
ferences that may still exist. Study control
subjects were community based and may
not represent the general population of
women. Finally, the results presented
should be interpreted keeping in mind
that multiple comparisons were made.
We are aware of the lack of unanimity of
opinionregardingthestatisticalapproach
when adjusting the statistical testing for
manycomparisons(22).Becausemanyof
our hypotheses are nested, and not inde-
pendent, we feel that using a Bonferroni
approach is overly conservative. How-
ever, we have interpreted our results with
caution and believe they are stronger
whenconsideredasawholeratherthanas
independent statistical tests.
OurﬁndingsdemonstratelowerBMD
in young women with type 1 diabetes
compared with control subjects. The dif-
ferences are seen at early ages and may
impact future fracture risk. Although
bone density testing is not routinely per-
formed in young women, these data sug-
gest that screening may be important in
young women with type 1 diabetes. In
addition, these women should be coun-
seledregardinglifestyleinterventionsthat
may improve bone health, including ade-
quate intake of calcium and vitamin D,
and exercise.
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